1. Home
  2. GRNQ vs HBIO Comparison

GRNQ vs HBIO Comparison

Compare GRNQ & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

HOLD

Current Price

$1.56

Market Cap

29.6M

Sector

Technology

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.09

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRNQ
HBIO
Founded
2013
1901
Country
Malaysia
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Laboratory Analytical Instruments
Sector
Technology
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
29.6M
26.5M
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
GRNQ
HBIO
Price
$1.56
$6.09
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
16.6K
22.0K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,673,997.00
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
24.55
N/A
52 Week Low
$1.21
$0.38
52 Week High
$3.18
$7.50

Technical Indicators

Market Signals
Indicator
GRNQ
HBIO
Relative Strength Index (RSI) 51.04 52.30
Support Level $1.63 $6.05
Resistance Level $1.87 $6.79
Average True Range (ATR) 0.12 0.37
MACD 0.04 -0.03
Stochastic Oscillator 73.33 38.37

Price Performance

Historical Comparison
GRNQ
HBIO

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: